金誠信(603979.SH)認購加拿大Cordoba Minerals Corp公司9137.25萬股股份
格隆匯11月17日丨金誠信(603979.SH)公告,認購加拿大 Cordoba Minerals Corp.股份。金誠信礦業管理股份有限公司下屬全資子公 司開元礦業投資有限公司擬與加拿大 Cordoba Minerals Corp. (以下簡稱“目標公司”,為一家在加拿大多倫多證券交 易所上市的公司)於 2019 年 11 月 16 日簽署《股份認購協議》,開元礦業 以 0.12 加元/股的價格認購目標公司 9137.25萬股普通股,認購金額合計 1096.47萬加元,此次股份認購完成後,開元礦業將持有目標公司已發行普 通股的 19.9%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.